U.S. Centers for Disease Control and Prevention has identified a total of 216 cases of heart inflammation after the first dose of an mRNA shot and another 573 cases after the second dose.
U.S. public health advisers will meet to discuss a possible link between Covid-19 traits using messenger RNA technology and inflammation of the heart after hundreds of vaccinated people have experienced a condition called myocarditis.
The Immunization Practices Advisory Committee of the Centers for Disease Control and Prevention will meet on June 18 to discuss an increase in reported cases of the disease, especially among adolescents and young adults. Covid vaccines manufactured by Moderna Inc. and its partners Pfizer Inc. and BioNTech SE use mRNA technology.
Since April, the CDC has experienced an increase in reports of myocarditis along with pericarditis, an inflammation of the membrane around the heart. The cases, although rare, have occurred mainly in male adolescents and young adults.
The CDC has identified a total of 216 cases of heart inflammation after the first dose of an mRNA trait and 573 cases after the second dose. The mean age of people with myocarditis or pericarditis after the first dose was 30 to 24 between the second dose cases. 475 cases among children under 30 were identified.
Most patients have responded well to treatment and rest, according to the agency, and more than 8 out of 10 have had total relief of their symptoms. The agency examines cases by age.
Approximately 130 million Americans have received the full two-dose regimen of one of two authorized mRNA vaccines. Currently, many teens have received the first dose of the Pfizer-BioNTech vaccine, which was eliminated for teens 12 years of age or older on May 10th.
“We’re still learning about rates of myocarditis and pericarditis,” Tom Shimabukuro, a security expert at CDC’s National Center for Emerging and Zoonotic Infectious Diseases, said Thursday at a meeting of the Food and Drug Administration group. “As we gather more information, we will begin to get a better idea of post-vaccination rates and look forward to getting more detailed information by age groups.”
Shimabukuro said U.S. data is consistent with the results of Israel’s vaccinated population.
“It’s hard to deny that there is any event that looks like it’s happening,” Cody Meissner, head of the pediatric infectious disease division at Tufts Medical Center, said at the FDA advisory committee meeting on Thursday.